Targeting TGFβ signal transduction for cancer therapy
Open accessThe DOI matches its Crossref record; 329 of the 330 references it cites were found in a registry or an index.
Abstract
Transforming growth factor-β (TGFβ) family members are structurally and functionally related cytokines that have diverse effects on the regulation of cell fate during embryonic development and in the maintenance of adult tissue homeostasis. Dysregulation of TGFβ family signaling can lead to a plethora of developmental disorders and diseases, including cancer, immune dysfunction, and fibrosis. In this review, we focus on TGFβ, a well-characterized family member that has a dichotomous role in cancer progression, acting in early stages as a tumor suppressor and in late stages as a tumor promoter. The functions of TGFβ are not limited to the regulation of proliferation, differentiation, apoptosis, epithelial-mesenchymal transition, and metastasis of cancer cells. Recent reports have related TGFβ to effects on cells that are present in the tumor microenvironment through the stimulation of extracellular matrix deposition, promotion of angiogenesis, and suppression of the anti-tumor immune reaction. The pro-oncogenic roles of TGFβ have attracted considerable attention because their intervention provides a therapeutic approach for cancer patients. However, the critical function of TGFβ in maintaining tissue homeostasis makes targeting TGFβ a challenge. Here, we review the pleiotropic functions of TGFβ in cancer initiation and progression, summarize the recent clinical advancements regarding TGFβ signaling interventions for cancer treatment, and discuss the remaining challenges and opportunities related to targeting this pathway. We provide a perspective on synergistic therapies that combine anti-TGFβ therapy with cytotoxic chemotherapy, targeted therapy, radiotherapy, or immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“TGF‐β therapeutics have recently shown great promise with the use of TGF‐β‐neutralizing antibodies and ligand traps, which inhibit the binding of TGF‐β with its receptors [155].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [155]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“PD-L1 is a transmembrane ligand expressed on the surface of cancer cells, tumor-infiltrating DCs and macrophages, and binds to PD-1 receptor located in the plasma membrane of cytotoxic CD8 T cells to suppress effector T cell antitumor function.(272) CTLA4 is a a Chemo/Radio-therapy”
BackgroundMolecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Structural absorption by barbule microstructures of super black bird of paradise feathers
McCoy, D. E., Feo, T., Harvey, T. A., & Prum, R. O. (2018) · Nature Communications · doi:10.1038/s41467-017-02088-w · Cited by 7,424
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 1×
“TGFβ has also been found to drive immune response evasion and attenuate the tumor response to anti-PD-L1 therapy by contributing to the exclusion of CD8 effector T cells.(275,276) In addition, the unsuccessful antitumor activity of chimeric antigen receptor (CAR) T cell therapy has been attributed in part to TGFβ-indu…”
BackgroundPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 1×
“However, only 15% of patients respond to immunotherapy.(274) Anti-PD-1 therapy not only initiates a tumor rejection program, but also induces a competing TGFβ-driven immunosuppressive program.”
BackgroundThe biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · cited 1×
“receptor expressed on Treg cells and downregulates immune responses.(273) Immune checkpoint inhibitors (ICIs) are currently at the forefront of cancer therapy, as they display successful longlasting antitumor efficacy, even for certain metastatic cancers.”
BackgroundOlive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170 · cited 1×
“CAFs surround and throughout the tumor often restrict the accessibility of anti-cancer drugs to tumor cells since the dense CAFs with stiff surrounding matrix can reduce the density of blood vessels and form a physical barrier surrounding the tumor cells.(149) In hypoxic TME, CAF-secreted TGFβ2 can cooperate with hypo…”
BackgroundMassagué, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3434 · Cited by 3,128 · cited 1×
“In different cell types and/or conditions, TGFβ can have different, even opposite, effects.(16) In normal and premalignant cells, TGFβ predominantly acts as a tumor suppressor by inhibiting cell proliferation, promoting apoptosis, and maintaining genome stability.”
BackgroundMolecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114 · cited 2×
“Therefore, costimulatory signal agonists and coinhibitory signal antagonists have been applied in cancer immunotherapy, of which CTLA4, PD-1, and its partner programmed death-ligand 1 (PD-L1) are the most studied.(271) PD-L1 is a transmembrane ligand expressed on the surface of cancer cells, tumor-infiltrating DCs and…”
BackgroundMethodShull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985 · cited 1×
“TGFβ1-deficient mice either die of vascular defects during embryogenesis or autoimmune disease postnatally.(8,9) Mice deficient in TGFβ2 have defects in cardiac septation and valve remodeling,(10) and mice lacking TGFβ3 have pulmonary defects and cleft palate.”
BackgroundDistinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., Corbo, V., Oni, T. E., Hearn, S. A., Lee, E. J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162024 · Cited by 2,590
Transforming Growth Factor-β Signaling in Immunity and Cancer
Batlle, E., & Massagué, J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.024 · Cited by 2,366 · cited 3×
“Moreover, TGFβ can create a beneficial TME by acting in a paracrine manner to activate cancer-associated fibroblasts (CAFs), promote angiogenesis, produce extracellular matrix (ECM), and suppress anti-tumor immune reaction to trigger cancer progression and promote metastasis.(3,4,20) Many preclinical results from in v…”
BackgroundMechanism of activation of the TGF-β receptor
Wrana, J. L., Attisano, L., Wieser, R., Ventura, F., & Massagué, J. (1994) · Nature · doi:10.1038/370341a0 · Cited by 2,337 · cited 1×
“TGFβ binding triggers TβRII to transphosphorylate TβRI at specific serine/threonine residues that are located in the intracellular juxtamembrane region enriched with glycine and serine residues (the GS domain).(51,52) After the extracellular signal is successfully transduced across the plasma membrane, activated TβRI…”
BackgroundDPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337 · cited 2×
“For example, TβRII mutations are frequently found in colorectal cancer (CRC),90 SMAD2 mutations have been reported in CRC, hepatocellular carcinoma (HCC), and lung cancer,91,92 and the deletion or mutation of SMAD4 is often identified in pancreatic cancer, CRC, and HCC.93,94 There are several advanced tumors that stil…”
BackgroundInactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability
Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., et al. (1995) · Science · doi:10.1126/science.7761852 · Cited by 2,270
Elyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A., Teinor, J. A., Belleau, P., Biffi, G., Lucito, M. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0094 · Cited by 2,241
Guidelines and definitions for research on epithelial-mesenchymal transition
Yang, J., Antin, P., Berx, G., Blanpain, C., Brabletz, T., Bronner, M., Campbell, K., Cano, A., Casanova, J., Christofori, G., et al. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0237-9 · Cited by 2,226 · cited 1×
“This has been referred to as epithelial cell plasticity (EMP).(125) TGFβ can induce different states of EMP and the cellular response to TGFβ is context-dependent; inflammatory factors, Wnt, Notch, Hippo, and Hedgehog interplay with TGFβ to orchestrate the EMP response.”
BackgroundRoles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883
TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function
Zhou, L., Lopes, J. E., Chong, M. M. W., Ivanov, I. I., Min, R., Victora, G. D., Shen, Y., Du, J., Rubtsov, Y. P., Rudensky, A. Y., et al. (2008) · Nature · doi:10.1038/nature06878 · Cited by 1,863
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851 · cited 1×
“TGFβ has also been found to drive immune response evasion and attenuate the tumor response to anti-PD-L1 therapy by contributing to the exclusion of CD8 effector T cells.(275,276) In addition, the unsuccessful antitumor activity of chimeric antigen receptor (CAR) T cell therapy has been attributed in part to TGFβ-indu…”
BackgroundIdentification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling
Nakao, A., Afrakhte, M., Morn, A., Nakayama, T., Christian, J. L., Heuchel, R., Itoh, S., Kawabata, M., Heldin, N.-E., Heldin, C.-H., et al. (1997) · Nature · doi:10.1038/39369 · Cited by 1,809
Non-Smad pathways in TGF-β signaling
Zhang, Y. E. (2009) · Cell Research · doi:10.1038/cr.2008.328 · Cited by 1,749 · cited 1×
“Besides, TGFβ can induce the phosphorylation of Src homology domain 2-containing protein (SHC) and then recruit growth factor receptor-binding protein 2 (GRB2) and son of sevenless (SOS) to activate the extracellular signalregulated kinase (ERK) pathway through the RAS, RAF, and mitogen-activated protein kinase (MEK)…”
BackgroundDerynck, R., Jarrett, J. A., Chen, E. Y., Eaton, D. H., Bell, J. R., Assoian, R. K., Roberts, A. B., Sporn, M. B., & Goeddel, D. V. (1985) · Nature · doi:10.1038/316701a0 · Cited by 1,667 · cited 1×
“BIOAVAILABILITY AND ACTIVATION OF TGFΒ LIGANDS TGFβ is synthesized as a large precursor protein in the rough endoplasmic reticulum, it consists of a signal peptide, a large Nterminal pro-segment termed latency-associated peptide (LAP), and a short C-terminal mature peptide.(26,27) The pro-peptide assembles into a homo…”
BackgroundMaking sense of latent TGFβ activation
Annes, J. P., Munger, J. S., & Rifkin, D. B. (2003) · Journal of Cell Science · doi:10.1242/jcs.00229 · Cited by 1,628
Assoian, R. K., Komoriya, A., Meyers, C. A., Miller, D. M., & Sporn, M. B. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32345-7 · Cited by 1,598
Growth factors from murine sarcoma virus-transformed cells.
de Larco, J. E., & Todaro, G. J. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.8.4001 · Cited by 1,461
Sanford, L. P., Ormsby, I., Groot, A. C. G.-D., Sariola, H., Friedman, R., Boivin, G. P., Cardell, E. L., & Doetschman, T. (1997) · Development · doi:10.1242/dev.124.13.2659 · Cited by 1,447
Immune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,371 · cited 2×
“Coinhibitory signals increase T cell exhaustion and dysfunction, and this process engages coinhibitory molecules, such as PD-1, cytotoxic Tlymphocyte-associated protein 4 (CTLA4), lymphocyte activation gene 3 (LAG3), T cell immunoglobulin domain and mucin domain 3 (TIM3), and sialic acid-binding immunoglobulin-type le…”
BackgroundTGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355
Hayashi, H., Abdollah, S., Qiu, Y., Cai, J., Xu, Y.-Y., Grinnell, B. W., Richardson, M. A., Topper, J. N., Gimbrone, M. A., Wrana, J. L., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80303-7 · Cited by 1,334
IRAK-M Is a Negative Regulator of Toll-like Receptor Signaling
Kobayashi, K., Hernandez, L. D., Galán, J. E., Janeway, C. A., Medzhitov, R., & Flavell, R. A. (2002) · Cell · doi:10.1016/s0092-8674(02)00827-9 · Cited by 1,286 · cited 1×
“IL1 receptor-associated kinase M (IRAKM) is a potent negative regulator of Toll-like receptor (TLR) signaling and is predominantly expressed in macrophages.(178) By inducing IRAK-M expression and antagonizing TLR signaling, TGFβ protects tumors from the potential TLR-mediated antitumor activities of macrophages.”
BackgroundSmad7 Binds to Smurf2 to Form an E3 Ubiquitin Ligase that Targets the TGFβ Receptor for Degradation
Kavsak, P., Rasmussen, R. K., Causing, C. G., Bonni, S., Zhu, H., Thomsen, G. H., & Wrana, J. L. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00134-9 · Cited by 1,205
Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo
Crawford, S. E., Stellmach, V., Murphy-Ullrich, J. E., Ribeiro, S. M. F., Lawler, J., Hynes, R. O., Boivin, G. P., & Bouck, N. (1998) · Cell · doi:10.1016/s0092-8674(00)81460-9 · Cited by 1,174 · cited 5×
“2a).3,31,36 Thrombospondin (TSP) is another activator of latent TGFβ that is present in the ECM; upon direct binding to LAP, TSP can induce the release of active TGFβ.37 In addition, the latent TGFβ binding protein (LTBP) can covalently bind to LAP, which facilitates the deposition of the SLC in the ECM and forms the…”
BackgroundInfluentialTGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis
Hao, Y., Baker, D., & ten Dijke, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112767 · Cited by 1,142 · cited 2×
“4a).(19) EMT has diverse phenotypic manifestations with intermediate epithelial/mesenchymal states and is a reversible process.”
BackgroundBalancing the activation state of the endothelium via two distinct TGF-beta type I receptors
Goumans, M.-J. (2002) · The EMBO Journal · doi:10.1093/emboj/21.7.1743 · Cited by 1,123 · cited 2×
“5b).(160,161) Indirectly, the expression of some key angiogenic factors, such as VEGF, CTGF, and fibroblast growth factor 2 (FGF2), can be induced by the TGFβ–ALK5 signaling axis.”
BackgroundDependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation
Calon, A., Espinet, E., Palomo-Ponce, S., Tauriello, D. V. F., Iglesias, M., Céspedes, M. V., Sevillano, M., Nadal, C., Jung, P., Zhang, X. H.-F., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.013 · Cited by 1,060
Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase
Lin, H. Y., Wang, X.-F., Ng-Eaton, E., Weinberg, R. A., & Lodish, H. F. (1992) · Cell · doi:10.1016/0092-8674(92)90152-3 · Cited by 1,057
Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052
Kaartinen, V., Voncken, J. W., Shuler, C., Warburton, D., Bu, D., Heisterkamp, N., & Groffen, J. (1995) · Nature Genetics · doi:10.1038/ng1295-415 · Cited by 1,031 · cited 1×
“Mice deficient in TGFβ2 have defects in cardiac septation and valve remodeling,(10) and mice lacking TGFβ3 have pulmonary defects and cleft palate.(11,12) TGFβ1 is the most abundant and studied isoform, and it is particularly highly enriched in platelets and bone.”
BackgroundDefective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice
Dickson, M. C., Martin, J. S., Cousins, F. M., Kulkarni, A. B., Karlsson, S., & Akhurst, R. J. (1995) · Development · doi:10.1242/dev.121.6.1845 · Cited by 1,029
Breast Tumor Cell Lines From Pleural Effusions2
Cailleau, R., Young, R., Olivé, M., & Reeves, W. J. (1974) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/53.3.661 · Cited by 1,015 · cited 1×
“4c.(130) MDA-MB-231 is highly aggressive and its metastasis to bone occurs in a TGFβ/SMAD-dependent manner.”
BackgroundLatent TGF-β structure and activation
Shi, M., Zhu, J., Wang, R., Chen, X., Mi, L., Walz, T., & Springer, T. A. (2011) · Nature · doi:10.1038/nature10152 · Cited by 1,013 · cited 1×
“2).(29,30) For the activation of latent TGFβ, the mature TGFβ portions need to dissociate from the LAP portions.”
BackgroundDiscovery of Endothelial to Mesenchymal Transition as a Source for Carcinoma-Associated Fibroblasts
Zeisberg, E. M., Potenta, S., Xie, L., Zeisberg, M., & Kalluri, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-3127 · Cited by 1,011 · cited 1×
“5a).(145,146) In turn, CAFs autocrine TGFβ can serve as an attractant to recruit more fibroblasts into the TME around the tumor invasion front and promote metastasis.”
BackgroundBhowmick, N. A., Ghiassi, M., Bakin, A., Aakre, M., Lundquist, C. A., Engel, M. E., Arteaga, C. L., & Moses, H. L. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.1.27 · Cited by 1,004
Targeting TGF-β Signaling in Cancer
Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003 · cited 4×
“Many preclinical results from in vitro cell models and in vivo animal models have shown the great potential of anti-tumor therapeutics with TGFβ-neutralizing antibodies and ligand traps that block the interaction of TGFβ with its receptors or selective small-molecule TGFβ receptor kinase inhibitors.(21,22) However, re…”
BackgroundInfluentialBakin, A. V., Tomlinson, A. K., Bhowmick, N. A., Moses, H. L., & Arteaga, C. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005912200 · Cited by 992
Yin, J. J., Selander, K., Chirgwin, J. M., Dallas, M., Grubbs, B. G., Wieser, R., Massagué, J., Mundy, G. R., & Guise, T. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci3523 · Cited by 986 · cited 1×
“MDA-MB-231 is highly aggressive and its metastasis to bone occurs in a TGFβ/SMAD-dependent manner.(101,119,131)”
BackgroundProteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium.
Lyons, R. M., Keski-Oja, J., & Moses, H. L. (1988) · The Journal of cell biology · doi:10.1083/jcb.106.5.1659 · Cited by 963 · cited 2×
“5) to dissociate the LAP portion from the mature protein.(31,32) In addition, reactive oxygen species can activate TGFβ in vitro by destroying the ability of LAP to bind to mature TGFβ via oxidative modification.”
BackgroundTGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · cited 2×
“Perspectives on the synergy of combination therapies Increased TGFβ activity has been implicated in the resistance to various anticancer therapies, including cytotoxic chemotherapy, targeted therapy, radiotherapy, and immunotherapy.(4) Therefore, combining anti-TGFβ therapy with these established strategies may dampen…”
BackgroundMiettinen, P. J., Ebner, R., Lopez, A. R., & Derynck, R. (1994) · The Journal of cell biology · doi:10.1083/jcb.127.6.2021 · Cited by 937
Roberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M., & Sporn, M. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5339 · Cited by 919
Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., Carbone, D. P., Matrisian, L. M., Richmond, A., Lin, P. C., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.004 · Cited by 918
Transforming growth factor–β3 is required for secondary palate fusion
Proetzel, G., Pawlowski, S. A., Wiles, M. V., Yin, M., Boivin, G. P., Howles, P. N., Ding, J., Ferguson, M. W. J., & Doetschman, T. (1995) · Nature Genetics · doi:10.1038/ng1295-409 · Cited by 908
Harmancı, A. S., Youngblood, M. W., Clark, V. E., Coşkun, S., Henegariu, O., Duran, D., Erson-Omay, E. Z., Kaulen, L. D., Lee, T. I., Abraham, B. J., et al. (2018) · Nature Communications · doi:10.1038/ncomms16215 · Cited by 905
Betaglycan presents ligand to the TGFβ signaling receptor
López-Casillas, F., Wrana, J. L., & Massagué, J. (1993) · Cell · doi:10.1016/0092-8674(93)90368-z · Cited by 901 · cited 1×
“Betaglycan can present TGFβ to the TGFβ receptor complex, which is present at low levels but high affinity, thereby facilitating signaling.(47) The TGFβ2 isoform is, in particular, dependent on TβRIII for signaling.”
BackgroundRegulation of the Polarity Protein Par6 by TGFß Receptors Controls Epithelial Cell Plasticity
Ozdamar, B., Bose, R., Barrios-Rodiles, M., Wang, H.-R., Zhang, Y., & Wrana, J. L. (2005) · Science · doi:10.1126/science.1105718 · Cited by 881 · cited 1×
“TβRII can directly phosphorylate the cell polarity regulator PAR6 that regulates tight junctions and cell migration.(107) TGFβ also induces the activation of TGFβ-activated kinase 1 (TAK1) to stimulate c-Jun NH2-terminal kinase (JNK) and p38 mitogenactivated protein kinase (MAPK) and nuclear factor κ-light-chain enhan…”
BackgroundCancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
Liu, T., Han, C., Wang, S., Fang, P., Ma, Z., Xu, L., & Yin, R. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0770-1 · Cited by 860
Dominguez, C. X., Müller, S., Keerthivasan, S., Koeppen, H., Hung, J., Gierke, S., Breart, B., Foreman, O., Bainbridge, T. W., Castiglioni, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0644 · Cited by 857 · cited 3×
“It will be interesting to explore if the targeting of LRRC15 CAF in the TME will boost the response of cancer patients towards immune checkpoint blockade therapy.(154)”
BackgroundInfluentialTGF-β Activation and Function in Immunity
Travis, M. A., & Sheppard, D. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120257 · Cited by 856 · cited 1×
“An increase number of studies showed that integrin-induced TGFβ signaling pathway modulates the tumor stroma and in particular the immune microenvironment.(200) Thus, besides their role to promote cell proliferation, survival, and migration, the ability of αv integrins to stimulate TGFβ activation contributes to cance…”
BackgroundOh, S. P., Seki, T., Goss, K. A., Imamura, T., Yi, Y., Donahoe, P. K., Li, L., Miyazono, K., ten Dijke, P., Kim, S., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.6.2626 · Cited by 851 · cited 1×
“In the presence of endoglin, the TGFβ-ALK1 signaling axis can directly promote endothelial cell proliferation and migration.(160,166) Moreover, the JNK pathway also mediates the proangiogenic response of TGFβ in endothelial cells.”
BackgroundContextual determinants of TGFβ action in development, immunity and cancer
David, C. J., & Massagué, J. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0007-0 · Cited by 851
Eppert, K., Scherer, S. W., Ozcelik, H., Pirone, R., Hoodless, P., Kim, H., Tsui, L.-C., Bapat, B., Gallinger, S., Andrulis, I. L., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)80128-2 · Cited by 845
The regulation of TGFβ signal transduction
Moustakas, A., & Heldin, C.-H. (2009) · Development · doi:10.1242/dev.030338 · Cited by 832
Bartoschek, M., Oskolkov, N., Bocci, M., Lövrot, J., Larsson, C., Sommarin, M., Madsen, C. D., Lindgren, D., Pekar, G., Karlsson, G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07582-3 · Cited by 826 · cited 1×
“For example in breast tumors, at least four distinct CAF subpopulations, that is, vascular CAFs, matrix CAFs, cycling CAFs, and developmental CAFs (dCAFs), were defined.(136) In pancreatic tumors, CAFs have been classified into inflammatory CAFs, which are found distant from tumor foci with high IL6 and low α-smooth m…”
BackgroundSpecificity, versatility, and control of TGF-β family signaling
Derynck, R., & Budi, E. H. (2019) · Science Signaling · doi:10.1126/scisignal.aav5183 · Cited by 785
Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta.
Postlethwaite, A. E., Keski-Oja, J., Moses, H. L., & Kang, A. H. (1987) · The Journal of experimental medicine · doi:10.1084/jem.165.1.251 · Cited by 777
FRANZEN, P. (1993) · Cell · doi:10.1016/0092-8674(93)90489-d · Cited by 766
Battegay, E. J., Raines, E. W., Seifert, R. A., Bowen-Pope, D. F., & Ross, R. (1990) · Cell · doi:10.1016/0092-8674(90)90448-n · Cited by 741
Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin.
Lyons, R. M., Gentry, L. E., Purchio, A. F., & Moses, H. L. (1990) · The Journal of cell biology · doi:10.1083/jcb.110.4.1361 · Cited by 737 · cited 1×
“2a).(3,31,36) Thrombospondin (TSP) is another activator of latent TGFβ that is present in the ECM; upon direct binding to LAP, TSP can induce the release of active TGFβ.”
The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP–dependent activation of TGF-β1
Mu, D., Cambier, S., Fjellbirkeland, L., Baron, J. L., Munger, J. S., Kawakatsu, H., Sheppard, D., Broaddus, V. C., & Nishimura, S. L. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200109100 · Cited by 729
Castriconi, R., Cantoni, C., Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R., Biassoni, R., Bottino, C., Moretta, L., & Moretta, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730640100 · Cited by 726
TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses
Yu, L. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf366 · Cited by 721
Signaling Receptors for TGF-β Family Members
Heldin, C.-H., & Moustakas, A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022053 · Cited by 711 · cited 1×
“Subsequently, the SMAD2/3–SMAD4 complex can translocate into the nucleus to activate or repress the expression of target genes.(55,56) SMAD7 is a target gene induced by TGFβ that encodes for a negative regulator of the TGFβ/SMAD signaling pathway by associating Mesenchymal tumor cells Fibroblasts Immune cells Endothel…”
BackgroundWieser, R., Wrana, J. L., & Massagué, J. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07214.x · Cited by 699
Non-Smad Signaling Pathways of the TGF-β Family
Zhang, Y. E. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022129 · Cited by 697 · cited 1×
“3c).(105) For example, TβRI activates RHO small GTPases and then regulates the activity of RHO-associated protein kinase and LIM kinase to phosphorylate cofilin, leading to actin cytoskeleton reorganization that regulates cell adhesion, motility, and growth.”
BackgroundSeoane, J., Le, H.-V., & Massagué, J. (2002) · Nature · doi:10.1038/nature01119 · Cited by 684
Yu, Y., Xiao, C.-H., Tan, L.-D., Wang, Q.-S., Li, X.-Q., & Feng, Y.-M. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.768 · Cited by 676
Chakravarthy, A., Khan, L., Bensler, N. P., Bose, P., & De Carvalho, D. D. (2018) · Nature Communications · doi:10.1038/s41467-018-06654-8 · Cited by 656
Kloss, C. C., Lee, J., Zhang, A., Chen, F., Melenhorst, J. J., Lacey, S. F., Maus, M. V., Fraietta, J. A., Zhao, Y., & June, C. H. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.003 · Cited by 648
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 639 · cited 1×
“CAR T cell therapy has demonstrated remarkable success by utilizing engineered T cells with tumor antigens that lead to the recognition and attack of tumor cells in blood cancers; however, this method still remains a big challenge for treating solid tumors partially due to TGFβ-mediated immunosuppression.(301) Inhibit…”
BackgroundTGF-β Family Signaling in the Control of Cell Proliferation and Survival
Zhang, Y., Alexander, P. B., & Wang, X.-F. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022145 · Cited by 626 · cited 1×
“3b.(69) In the early stage of tumorigenesis, TGFβ promotes the expression of cyclin-dependent kinase inhibitors, including p15, p21, p57, and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), to induce cell cycle arrest.”
BackgroundRegulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection
Sanjabi, S., Oh, S. A., & Li, M. O. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022236 · Cited by 621
Valcourt, U., Kowanetz, M., Niimi, H., Heldin, C.-H., & Moustakas, A. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-08-0658 · Cited by 610
TGF-β signaling in vascular biology and dysfunction
Goumans, M.-J., Liu, Z., & ten Dijke, P. (2009) · Cell Research · doi:10.1038/cr.2008.326 · Cited by 601 · cited 2×
“TGFβ can increase forkhead box P3 (FOXP3) gene expression,95 and decrease interferon-γ (IFNγ), MHC class I-chain-related molecules A (MICA), granzyme A/B, natural killer group 2 member D (NKG2D), natural cytotoxicity receptor 3 (NKP30), and Perforin gene expression to suppress immune function.96–99 Besides, TGFβ upreg…”
BackgroundTGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
Bhola, N. E., Balko, J. M., Dugger, T. C., Kuba, M. G., Sánchez, V., Sanders, M., Stanford, J., Cook, R. S., & Arteaga, C. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65416 · Cited by 590
Redox-mediated activation of latent transforming growth factor-beta 1
Barcellos-Hoff, M. H. (1996) · Molecular Endocrinology · doi:10.1210/me.10.9.1077 · Cited by 585
Madri, J. A., Pratt, B. M., & Tucker, A. M. (1988) · The Journal of cell biology · doi:10.1083/jcb.106.4.1375 · Cited by 573
TRAF6 Mediates Smad-Independent Activation of JNK and p38 by TGF-β
Yamashita, M., Fatyol, K., Jin, C., Wang, X., Liu, Z., & Zhang, Y. E. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.09.002 · Cited by 559
The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner
Sorrentino, A., Thakur, N., Grimsby, S., Marcusson, A., von Bulow, V., Schuster, N., Zhang, S., Heldin, C.-H., & Landström, M. (2008) · Nature Cell Biology · doi:10.1038/ncb1780 · Cited by 553
A Self-Enabling TGFβ Response Coupled to Stress Signaling
Kang, Y., Chen, C.-R., & Massagué, J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00109-6 · Cited by 550 · cited 1×
“Inhibitor of DNA binding 1 (ID1) protein functions as a cell differentiation inhibitor and stimulator of cell proliferation, and long-term stimulation of cells by TGFβ can silence the ID1 promoter and thereby drive epithelial cells to enter into a cytostatic program.(80) ID1 was also shown to mediate the escape of pan…”
BackgroundLymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity
Swartz, M. A., & Lund, A. W. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3186 · Cited by 544
Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway
Kang, Y., He, W., Tulley, S., Gupta, G. P., Serganova, I., Chen, C.-R., Manova-Todorova, K., Blasberg, R., Gerald, W. L., & Massagué, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506517102 · Cited by 532 · cited 1×
“MDA-MB-231 is highly aggressive and its metastasis to bone occurs in a TGFβ/SMAD-dependent manner.(101,119,131)”
BackgroundTGF‐β activates Erk MAP kinase signalling through direct phosphorylation of ShcA
Lee, M. K., Pardoux, C., Hall, M. C., Lee, P. S., Warburton, D., Qing, J., Smith, S. M., & Derynck, R. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601818 · Cited by 527
Activation of the Erk Pathway Is Required for TGF-β1-Induced EMT In Vitro
Xie, L., Law, B. K., Chytil, A. M., Brown, K. A., Aakre, M. E., & Moses, H. L. (2004) · Neoplasia · doi:10.1593/neo.04241 · Cited by 523
Cartilage-inducing factor-A. Apparent identity to transforming growth factor-beta.
Seyedin, S. M., Thompson, A. Y., Bentz, H., Rosen, D. M., McPherson, J. M., Conti, A., Siegel, N. R., Galluppi, G. R., & Piez, K. A. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38436-3 · Cited by 521 · cited 1×
“TGFβ1 is the most abundant and studied isoform, and it is particularly highly enriched in platelets and bone.(13,14) TGFβ signaling has attracted the interest of cancer biologists because of its numerous roles in regulating cancer cell functions, including cell cycle progression, apoptosis, adhesion, and differentiati…”
BackgroundTyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Pottier, C., Fresnais, M., Gilon, M., Jérusalem, G., Longuespée, R., & Sounni, N. E. (2020) · Cancers · doi:10.3390/cancers12030731 · Cited by 515 · cited 1×
“Examples of such small-molecule compounds are selective tyrosine kinase inhibitors.(257) Selective small-molecule inhibitors have less severe side effects than standard chemotherapy, but both types of therapy can lead to therapy resistance and relapse, as some cells within the heterogeneous tumor population survive an…”
BackgroundRønnov‐Jessen, L., & Petersen, O. W. (1993) · PubMed · Cited by 513
A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1.
Miyazono, K., Olofsson, A., Colosetti, P., & Heldin, C. H. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb08049.x · Cited by 509
Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., Yu, H., Qin, G., Sircar, A., Hernández, V. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5488 · Cited by 494 · cited 1×
“The fusion protein can target both TGFβ- and PD-L1mediated signaling pathways, and it displayed promising results by eliciting antitumor activity in multiple mouse cancer models.(289) M7824 showed a manageable safety profile and encouraging clinical efficacy in phase 1 clinical trials, including patients with advanced…”
BackgroundTGF-β signaling in vascular fibrosis
RUIZORTEGA, M., RODRIGUEZVITA, J., SANCHEZLOPEZ, E., CARVAJAL, G., & EGIDO, J. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.02.008 · Cited by 492 · cited 2×
“TGFβ can increase forkhead box P3 (FOXP3) gene expression,95 and decrease interferon-γ (IFNγ), MHC class I-chain-related molecules A (MICA), granzyme A/B, natural killer group 2 member D (NKG2D), natural cytotoxicity receptor 3 (NKP30), and Perforin gene expression to suppress immune function.96–99 Besides, TGFβ upreg…”
BackgroundTGF-β orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1
Su, J., Morgani, S. M., David, C. J., Wang, Q., Er, E. E., Huang, Y.-H., Basnet, H., Zou, Y., Shu, W., Soni, R. K., et al. (2020) · Nature · doi:10.1038/s41586-019-1897-5 · Cited by 492 · cited 1×
“A recent study discovered that the RAS-responsive element-binding protein 1 (RREB1) provides a molecular link between RAS and TGFβ pathways for coordinated induction of a developmental and fibrogenic EMT pathway.(113) These non-SMAD signaling pathways are not unique to TGFβ; some are tightly regulated by receptor tyro…”
BackgroundTGFβ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b
Seoane, J., Pouponnot, C., Staller, P., Schader, M., Eilers, M., & Massagué, J. (2001) · Nature Cell Biology · doi:10.1038/35070086 · Cited by 489
Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090353 · Cited by 487
Abdollah, S., Macı́as-Silva, M., Tsukazaki, T., Hayashi, H., Attisano, L., & Wrana, J. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.44.27678 · Cited by 481 · cited 1×
“After the extracellular signal is successfully transduced across the plasma membrane, activated TβRI initiates intracellular signaling by phosphorylating SMAD2/3 at their two extreme C-terminal serine residues.(53,54) Thereafter, phosphorylated SMAD2/3 dissociates promptly from TβRI and assemble into a heteromeric com…”
BackgroundBruna, A., Darken, R. S., Rojo, F., Ocaña, A., Peñuelas, S., Arias, A., Paris, R., Tortosa, A., Mora, J., Baselga, J., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.023 · Cited by 472
TGF-β1 – A truly transforming growth factor in fibrosis and immunity
Lodyga, M., & Hinz, B. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.12.010 · Cited by 458 · cited 5×
“2a).3,31,36 Thrombospondin (TSP) is another activator of latent TGFβ that is present in the ECM; upon direct binding to LAP, TSP can induce the release of active TGFβ.37 In addition, the latent TGFβ binding protein (LTBP) can covalently bind to LAP, which facilitates the deposition of the SLC in the ECM and forms the…”
BackgroundInfluentialStupp, R., Hegi, M. E., Neyns, B., Goldbrunner, R., Schlegel, U., Clement, P. M. J., Grabenbauer, G. G., Ochsenbein, A. F., Simon, M., Dietrich, P.-Y., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6650 · Cited by 454
Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq142 · Cited by 433
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Huang, S., Hölzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.10.035 · Cited by 430 · cited 1×
“Treatment with the TβRI kinase inhibitor galunisertib (LY2157299) sensitized the therapeutic response of metastatic non-small cell lung cancers with downregulated MED12 to RTK inhibitors.(263) In radiotherapy, ionizing radiation is used to kill or control the growth of malignant cells.”
BackgroundCancer-Associated Fibroblasts as Another Polarized Cell Type of the Tumor Microenvironment
Augsten, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00062 · Cited by 427 · cited 1×
“Next to tumor-promoting CAFs, also tumor-suppressive CAFs have been identified.(135) Within a tumor, the CAF population can be highly heterogeneous.”
BackgroundPiek, E., Moustakas, A., Kurisaki, A., Heldin, C.-H., & Dijke, P. T. (1999) · Journal of Cell Science · doi:10.1242/jcs.112.24.4557 · Cited by 426
TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors
Tang, N., Cheng, C., Zhang, X., Qiao, M., Li, N., Mu, W., Wei, X.-F., Han, W., & Wang, H. (2020) · JCI Insight · doi:10.1172/jci.insight.133977 · Cited by 413 · cited 1×
“Inhibiting TGFβ signaling in CART cells can boost their antitumor efficacy in solid tumors.(302,303) Other strategies also reported overcoming CART cell repression by interfering with TGFβ signaling, such as coexpression of the dominant-negative TβRII,(304) coexpression of TβRII-41BB to switch the TGFβ-suppressive sig…”
BackgroundEichhorn, P. J. A., Rodón, L., Gonzàlez-Juncà, A., Dirac, A., Gili, M., Martínez-Sáez, E., Aura, C., Barba, I., Peg, V., Prat, A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2619 · Cited by 409
Bachmann, M., Kukkurainen, S., Hytönen, V. P., & Wehrle-Haller, B. (2019) · Physiological Reviews · doi:10.1152/physrev.00036.2018 · Cited by 407 · cited 6×
“Integrins comprise α and β heterodimeric subunits that are both type I transmembrane receptors and are expressed in a wide range of cells.(42) Certain integrins have been demonstrated to interact with the Arg-Gly-Asp (RGD) motif of LAP and lead to the mechanical release of LAP by cellular contractions.”
BackgroundInfluentialStrauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2653 · Cited by 406
Processing of Transforming Growth Factor β1 Precursor by Human Furin Convertase
Dubois, C. M., Laprise, M.-H., Blanchette, F., Gentry, L. E., & Leduc, R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.18.10618 · Cited by 405 · cited 1×
“2).(29,30) For the activation of latent TGFβ, the mature TGFβ portions need to dissociate from the LAP portions.”
BackgroundTGF-β1-mediated fibroblast–myofibroblast terminal differentiation—the role of smad proteins
Evans, R. A., Tian, Y. A. C., Steadman, R., & Phillips, A. O. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00015-0 · Cited by 398
Pietenpol, J. A., Holt, J. T., Stein, R. W., & Moses, H. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.10.3758 · Cited by 398
Yang, D., Sun, Y., Hu, L., Zheng, H., Ji, P., Pecot, C. V., Zhao, Y., Reynolds, S., Cheng, H., Rupaimoole, R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.020 · Cited by 394
Jiao, S., Subudhi, S. K., Aparicio, A., Ge, Z., Guan, B., Miura, Y., & Sharma, P. (2019) · Cell · doi:10.1016/j.cell.2019.10.029 · Cited by 386 · cited 1×
“However, it induces the conversion of naive T cells into Treg cells (previously known as suppressor T cells) that suppress the immune response.(180) A recent study showed that depletion of TβRII in Dendritic cells Maturation Chemotaxis Antigen presentation Cytotoxic CD8+ T cells”
BackgroundSouchelnytskyi, S., Tamaki, K., Engström, U., Wernstedt, C., ten Dijke, P., & Heldin, C.-H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.44.28107 · Cited by 382 · cited 1×
“After the extracellular signal is successfully transduced across the plasma membrane, activated TβRI initiates intracellular signaling by phosphorylating SMAD2/3 at their two extreme C-terminal serine residues.(53,54) Thereafter, phosphorylated SMAD2/3 dissociates promptly from TβRI and assemble into a heteromeric com…”
BackgroundSignaling pathway cooperation in TGF-β-induced epithelial–mesenchymal transition
Derynck, R., Muthusamy, B. P., & Saeteurn, K. Y. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.09.001 · Cited by 374 · cited 1×
“TGFβ can induce different states of EMP and the cellular response to TGFβ is context-dependent; inflammatory factors, Wnt, Notch, Hippo, and Hedgehog interplay with TGFβ to orchestrate the EMP response.(126) In Fig.”
BackgroundDeckers, M., van Dinther, M., Buijs, J., Que, I., Löwik, C., van der Pluijm, G., & ten Dijke, P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3560 · Cited by 371 · cited 1×
“MDA-MB-231 is highly aggressive and its metastasis to bone occurs in a TGFβ/SMAD-dependent manner.(101,119,131)”
BackgroundNemunaitis, J., Dillman, R. O., Schwarzenberger, P. O., Senzer, N., Cunningham, C., Cutler, J., Tong, A., Kumar, P., Pappen, B., Hamilton, C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5335 · Cited by 367
TGF-β Signaling in Control of Cardiovascular Function
Goumans, M.-J., & ten Dijke, P. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022210 · Cited by 360 · cited 1×
“5b).(160,161) Indirectly, the expression of some key angiogenic factors, such as VEGF, CTGF, and fibroblast growth factor 2 (FGF2), can be induced by the TGFβ–ALK5 signaling axis.”
BackgroundCheifetz, S., Hernandez, H., Laiho, M., ten Dijke, P., Iwata, K. K., & Massagué, J. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30535-5 · Cited by 348
Immunoregulation by members of the TGFβ superfamily
Chen, W., & ten Dijke, P. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.112 · Cited by 347 · cited 1×
“Moreover, TGFβ can create a beneficial TME by acting in a paracrine manner to activate cancer-associated fibroblasts (CAFs), promote angiogenesis, produce extracellular matrix (ECM), and suppress anti-tumor immune reaction to trigger cancer progression and promote metastasis.(3,4,20) Many preclinical results from in v…”
BackgroundTGF-beta in CAF-mediated tumor growth and metastasis
Calon, A., Tauriello, D. V. F., & Batlle, E. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.008 · Cited by 342
Yamashita, H., ten Dijke, P., Franzén, P., Miyazono, K., & Heldin, C. H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32142-7 · Cited by 326
Ravi, R., Noonan, K. A., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., V. Artemov, A., Wysocki, P. T., Mehra, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02696-6 · Cited by 325
USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor
Zhang, L., Zhou, F., Drabsch, Y., Gao, R., Snaar-Jagalska, B. E., Mickanin, C., Huang, H., Sheppard, K.-A., Porter, J. A., Lu, C. X., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2522 · Cited by 324
Identification of another member of the transforming growth factor type beta gene family.
ten Dijke, P., Hansen, P., Iwata, K. K., Pieler, C., & Foulkes, J. G. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.13.4715 · Cited by 324 · cited 3×
“There are three highly structurally related mammalian TGFβ isoforms, that is, TGFβ1, TGFβ2, and TGFβ3.”
BackgroundChen, C.-R., Kang, Y., & Massagué, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.992 · Cited by 320
CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer
Pereira, B. A., Vennin, C., Papanicolaou, M., Chambers, C. R., Herrmann, D., Morton, J. P., Cox, T. R., & Timpson, P. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.09.010 · Cited by 314
Callahan, J. F., Burgess, J. L., Fornwald, J. A., Gaster, L. M., Harling, J. D., Harrington, F. P., Heer, J., Kwon, C., Lehr, R., Mathur, A., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010493y · Cited by 308 · cited 1×
“these advances allowed the pharmacological interference of key pathways with neutralizing antibodies against TGFβ or TGFβ receptor kinase inhibitors.(319,320) While preclinical studies in mouse models have shown great promise for TGFβ pharmacological agents, the role of TGFβ as a tumor suppressor and critical role in…”
BackgroundEpithelial to Mesenchymal Transition in Human Breast Cancer Can Provide a Nonmalignant Stroma
Petersen, O. W., Nielsen, H. L., Gudjonsson, T., Villadsen, R., Rank, F., Niebuhr, E., Bissell, M. J., & Rønnov-Jessen, L. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63834-5 · Cited by 305 · cited 1×
“5a).(145,146) In turn, CAFs autocrine TGFβ can serve as an attractant to recruit more fibroblasts into the TME around the tumor invasion front and promote metastasis.”
BackgroundJobling, M. F., Mott, J. D., Finnegan, M. T., Jurukovski, V., Erickson, A. C., Walian, P. J., Taylor, S. E., Ledbetter, S., Lawrence, C. M., Rifkin, D. B., et al. (2006) · Radiation Research · doi:10.1667/rr0695.1 · Cited by 300
Melisi, D., Garcia-Carbonero, R., Macarulla, T., Pezet, D., Deplanque, G., Fuchs, M., Trojan, J., Oettle, H., Kozloff, M., Cleverly, A., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0246-z · Cited by 294 · cited 1×
“Phase 1/2 clinical trials of this inhibitor for patients with metastatic prostate cancer/TNBC/ advanced HCC/rectal cancer/recurrent glioblastoma are ongoing.(213,215,216) A phase 2 study of this inhibitor for patients with advanced HCC showed acceptable safety and prolonged overall survival.”
BackgroundPhase I and Correlative Biology Study of Cilengitide in Patients With Recurrent Malignant Glioma
Nabors, L. B., Mikkelsen, T., Rosenfeld, S. S., Hochberg, F., Akella, N. S., Fisher, J. D., Cloud, G. A., Zhang, Y., Carson, K., Wittemer, S. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6514 · Cited by 290
TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
Park, B. V., Freeman, Z. T., Ghasemzadeh, A., Chattergoon, M. A., Rutebemberwa, A., Steigner, J., Winter, M. E., Huynh, T. V., Sebald, S. M., Lee, S.-J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1347 · Cited by 287 · cited 1×
“TGFβ promotes antigeninduced programmed cell death protein-1 (PD-1) expression in CD8 T cells, which causes T cell exhaustion.(185) Recently, researchers found that the TGFβ signal maintains the immunesuppressive identity of CD8 Treg cells.”
BackgroundFrequency of Smad gene mutations in human cancers.
Riggins, G. J., Kinzler, K. W., Vogelstein, B., & Thiagalingam, S. (1997) · PubMed · Cited by 285
Gentry, L. E., Lioubin, M. N., Purchio, A. F., & Marquardt, H. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.10.4162 · Cited by 284 · cited 1×
“BIOAVAILABILITY AND ACTIVATION OF TGFΒ LIGANDS TGFβ is synthesized as a large precursor protein in the rough endoplasmic reticulum, it consists of a signal peptide, a large Nterminal pro-segment termed latency-associated peptide (LAP), and a short C-terminal mature peptide.(26,27) The pro-peptide assembles into a homo…”
BackgroundGiaccone, G., Bazhenova, L. A., Nemunaitis, J., Tan, M., Juhász, E., Ramlau, R., van den Heuvel, M. M., Lal, R., Kloecker, G. H., Eaton, K. D., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.035 · Cited by 279 · cited 1×
“This vaccine did not meet its survival endpoint in a phase 3 clinical trial for NSCLC patients; however, it improved the overall survival of patients who had completed chemotherapy within the previous 12 weeks.(248)”
BackgroundTang, Y.-A., Chen, Y.-F., Bao, Y., Mahara, S., Yatim, S. M. J. M., Oguz, G., Lee, P. L., Feng, M., Cai, Y., Tan, E. Y., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801348115 · Cited by 277 · cited 1×
“In hypoxic TME, CAF-secreted TGFβ2 can cooperate with hypoxia-inducible factor to increase stemness phenotype and induce robust chemotherapy of cancer cells.(150) Radiation-induced TGFβ signaling can activate CAFs in the TME, which enhances the invasiveness of the associated tumor cells via promoting EMT.”
BackgroundTrotta, R., Col, J. D., Yu, J., Ciarlariello, D., Thomas, B., Zhang, X., Allard, J., Wei, M., Mao, H., Byrd, J. C., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.3784 · Cited by 275
Brandes, A. A., Carpentier, A. F., Kesari, S., Sepulveda-Sanchez, J. M., Wheeler, H. R., Chinot, O., Cher, L., Steinbach, J. P., Capper, D., Specenier, P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now009 · Cited by 273 · cited 1×
“However, in a phase 2 study of patients with recurrent glioblastoma, this inhibitor failed to improve the overall survival.(217) Vactosertib (TEW-7197) is another orally bioavailable kinase inhibitor of TβRI that revealed promising antitumor function in a mouse model of myeloma.”
BackgroundLocalized production of TGF-β mRNA in tumour promoter-stimulated mouse epidermis
Akhurst, R. J., Fee, F., & Balmaint, A. (1988) · Nature · doi:10.1038/331363a0 · Cited by 272 · cited 2×
“At an early stage of cancer, TGFβ mitigates myeloid proliferation and differentiation by repressing the expression of cytokine IFNγ.(171,172) Progressively, myeloid cells in advanced-stage cancer produce TGFβ and MMPs that further inhibit antitumor immune reactions and promote tumor metastasis.”
BackgroundRequirement for Activin a and Transforming Growth Factor--β1 Pro-Regions in Homodimer Assembly
Gray, A. M., & Mason, A. J. (1990) · Science · doi:10.1126/science.2315700 · Cited by 271 · cited 1×
“The pro-peptide assembles into a homodimer in which the LAP portions link via two disulfide bonds and the mature TGFβ moieties’ interaction is stabilized through a disulfide bond.(28) After cleavage of the precursor protein by the convertase furin in the Golgi complex, the LAP portions encircle the mature portions to…”
BackgroundRewiring T-cell responses to soluble factors with chimeric antigen receptors
Chang, Z. L., Lorenzini, M. H., Chen, X., Tran, U., Bangayan, N. J., & Chen, Y. Y. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2565 · Cited by 259
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
Formenti, S. C., Lee, P., Adams, S., Goldberg, J. D., Li, X., Xie, M. W., Ratikan, J. A., Felix, C., Hwang, L., Faull, K. F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3322 · Cited by 257 · cited 1×
“In a phase 2 clinical trial, the TGFβ-blocking antibody fresolimumab (GC1008) was combined with focal irradiation for the treatment of metastatic breast cancer, and it was found to prolong median overall survival and demonstrated a favorable systemic immune response.(268,269) In addition, fresolimumab (GC1008) combine…”
BackgroundZhang, S., Fei, T., Zhang, L., Zhang, R., Chen, F., Ning, Y., Han, Y., Feng, X.-H., Meng, A., & Chen, Y.-G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01636-06 · Cited by 255 · cited 1×
“SMAD7 can also antagonize TGFβ signaling in the nucleus by disrupting the formation of the functional SMAD–DNA complex.(60,61) Moreover, SMAD7 recruits E3 ubiquitin ligases such as SMAD ubiquitination regulatory factor 1/2 (SMURF1/2), WW domain-containing protein 1 (WWP1), and neural precursor cellexpressed developmen…”
BackgroundThe restriction point and control of cell proliferation
Planas-Silva, M. D., & Weinberg, R. A. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80076-2 · Cited by 250
Kelley, R. K., Gane, E., Assenat, E., Siebler, J., Galle, P. R., Merle, P., Hourmand, I. O., Cleverly, A., Zhao, Y., Gueorguieva, I., et al. (2019) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000056 · Cited by 247 · cited 2×
“A phase 2 study of this inhibitor for patients with advanced HCC showed acceptable safety and prolonged overall survival.(215) However, in a phase 2 study of patients with recurrent glioblastoma, this inhibitor failed to improve the overall survival.”
BackgroundHardee, M. E., Marciscano, A. E., Medina-Ramirez, C. M., Zagzag, D., Narayana, A., Lonning, S. M., & Barcellos-Hoff, M. H. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0546 · Cited by 246
Munger, J. S., Harpel, J. G., Giancotti, F. G., & Rifkin, D. B. (1998) · Molecular Biology of the Cell · doi:10.1091/mbc.9.9.2627 · Cited by 241
Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells
Li, S., Liu, M., Do, M. H., Chou, C., Stamatiades, E. G., Nixon, B. G., Shi, W., Zhang, X., Li, P., Gao, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2850-3 · Cited by 240 · cited 1×
“Recently, researchers engineered a bispecific receptor decoy named CD4 TGFβ Trap that selectively blocks TGF-β signaling in CD4 T cells and promotes reorganization of tumor vasculature and cancer cell death in a mouse mammary tumor virus promoter-driven Polyoma middle T-antigen transgenic mouse model of breast cancer.…”
BackgroundSaharinen, J., Taipale, J., & Keski-Oja, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00355.x · Cited by 239 · cited 2×
“2b).(39,40) Moreover, the latent TGFβ can also interact with the transmembrane glycoprotein A repetition predominant protein (GARP), which is expressed on the cell surface of regulatory T (Treg) cells, platelets, and endothelial cells to facilitate latent TGFβ activation (Fig.”
BackgroundJotzu, C., Alt, E., Welte, G., Li, J., Hennessy, B. T., Devarajan, E., Krishnappa, S., Pinilla, S., Droll, L., & Song, Y.-H. (2011) · Cellular Oncology · doi:10.1007/s13402-011-0012-1 · Cited by 236
Rodon, J., Carducci, M. A., Sepulveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1380 · Cited by 235 · cited 1×
“Galunisertib (LY2157299) has been applied as a therapy regimen of 2 weeks on and 2 weeks off drug treatment to reduce the (cardiac) side effects.(249) In addition, predictive biomarkers may aid in selecting patients who benefit most from treatment with anti-TGFβ agents.”
MethodTGF-β signaling in cancer metastasis
Xie, F., Ling, L., Van Dam, H., Zhou, F., & Zhang, L. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx123 · Cited by 231
Eskens, F. A. L. M., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Böttcher, S., Wynendaele, W., Drevs, J., Verweij, J., & van Oosterom, A. T. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00057-1 · Cited by 225
Martin, C. J., Datta, A., Littlefield, C., Kalra, A., Chapron, C., Wawersik, S., Dagbay, K. B., Brueckner, C. T., Nikiforov, A., Danehy, F. T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8456 · Cited by 224 · cited 2×
“The coadministration of SRK-181-mIgG1 together with anti-PD-1 inhibitors has been applied in the treatment of checkpoint blockade-resistant syngeneic mouse tumors that displayed an increased influx of intratumoral CD8 T cells and a lower level of immunosuppressive myeloid cells.(282) Researchers designed pH-responsive…”
BackgroundTGFβ: a sleeping giant awoken by integrins
Worthington, J. J., Klementowicz, J. E., & Travis, M. A. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.08.002 · Cited by 218
KURATOMI, G., KOMURO, A., GOTO, K., SHINOZAKI, M., MIYAZAWA, K., MIYAZONO, K., & IMAMURA, T. (2005) · Biochemical Journal · doi:10.1042/bj20040738 · Cited by 217
Heterogeneity of cancer‐associated fibroblasts: Opportunities for precision medicine
Kanzaki, R., & Pietras, K. (2020) · Cancer Science · doi:10.1111/cas.14537 · Cited by 213
Epithelial Cell Cultures From Normal Glandular Tissue of Mice 2
Owens, R. B., Smith, C. S., & Hackett, A. J. (1974) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/53.1.261 · Cited by 212 · cited 1×
“4b, we show that TGFβ promotes the EMT in non-transformed mouse mammary gland (NMuMG) epithelial cells.(127) The NMuMG cell line is a frequently used model system to investigate TGFβ-induced EMT.”
BackgroundLoke, P., MacDonald, A. S., Robb, A., Maizels, R. M., & Allen, J. E. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200009)30:9<2669::aid-immu2669>3.0.co;2-1 · Cited by 211
Teixeira, A. F., ten Dijke, P., & Zhu, H.-J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00605 · Cited by 211
Wiercinska, E., Naber, H. P. H., Pardali, E., van der Pluijm, G., van Dam, H., & ten Dijke, P. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1147-x · Cited by 208
Komuro, A., Imamura, T., Saitoh, M., Yoshida, Y., Yamori, T., Miyazono, K., & Miyazawa, K. (2004) · Oncogene · doi:10.1038/sj.onc.1207885 · Cited by 205
Targeted tumor therapy with the TGF-β2 antisense compound AP 12009
SCHLINGENSIEPEN, K., SCHLINGENSIEPEN, R., STEINBRECHER, A., HAU, P., BOGDAHN, U., FISCHERBLASS, B., & JACHIMCZAK, P. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.002 · Cited by 195 · cited 1×
“Trabedersen (AP12009) is a phosphonothioate antisense oligodeoxynucleotide that specifically targets TGFβ2 mRNA.(240) Trabedersen was evaluated in the phase 1 clinical studies in patients with melanoma/pancreatic cancer/CRC, and showed good safety and encouraging survival results.”
BackgroundKnudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1426519 · Cited by 195 · cited 1×
“The combination of an adenovirus cancer vaccine encoding tumor-associated antigen TWIST1 (Ad-TWIST) and bifunctional fusion protein M7824 that targets both TGFβ and PD-L1 displayed superior improvement of the antitumor efficacy as compared to Ad-TWIST monotherapy in multiple murine models of human solid tumors.(310) I…”
BackgroundYamashita, H., Ichijo, H., Grimsby, S., Morén, A., ten Dijke, P., & Miyazono, K. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42126-0 · Cited by 194
Heath, V. L., Murphy, E. E., Crain, C., Tomlinson, M. G., & O’Garra, A. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200009)30:9<2639::aid-immu2639>3.0.co;2-7 · Cited by 193
Shipley, G. D., Tucker, R. F., & Moses, H. L. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4147 · Cited by 189 · cited 1×
“CONCLUDING REMARKS TGFβ was discovered in the late 1970s/early 1980s,(313,314) and its role as a multifunctional regulator of normal and cancer cell growth became apparent shortly thereafter.(315) The purification of TGFβ and cloning of its complementary DNA, as well as the identification of TGFβ receptors, paved the…”
BackgroundYingling, J. M., McMillen, W. T., Yan, L., Huang, H., Sawyer, J. S., Graff, J., Clawson, D. K., Britt, K. S., Anderson, B. D., Beight, D. W., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23795 · Cited by 187 · cited 1×
“It showed favorable preclinical results for antitumor growth, for example, in Calu6 and EMT6-LM2 mouse tumor models.(210) In phase 1 clinical trials, this inhibitor exhibited acceptable safety and dose tolerability for patients with HCC/metastatic pancreatic cancer/malignant glioma/advanced solid tumors.”
BackgroundTGF-β suppresses type 2 immunity to cancer
Liu, M., Kuo, F., Capistrano, K. J., Kang, D., Nixon, B. G., Shi, W., Chou, C., Do, M. H., Stamatiades, E. G., Gao, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2836-1 · Cited by 187 · cited 1×
“CD4 T cells suppresses cancer progression as a result of tissue healing and remodeling of the blood vasculature, causing cancer hypoxia and death in distant avascular regions.(181) TGFβ can block the activation and maturation of cytotoxic CD8 T cells by repressing the tumor antigen processing and presentation of DCs a…”
Chen, R.-H., Su, Y.-H., Chuang, R. L., & Chang, T.-Y. (1998) · Oncogene · doi:10.1038/sj.onc.1202111 · Cited by 186 · cited 1×
“dependent manner.(111) Besides, TGFβ can induce the phosphorylation of Src homology domain 2-containing protein (SHC) and then recruit growth factor receptor-binding protein 2 (GRB2) and son of sevenless (SOS) to activate the extracellular signalregulated kinase (ERK) pathway through the RAS, RAF, and mitogen-activate…”
BackgroundPooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies
Roth, T. L., Li, P. J., Blaeschke, F., Nies, J. F., Apathy, R., Mowery, C., Yu, R., Nguyen, M. L. T., Lee, Y., Truong, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.039 · Cited by 186
Korkut, A., Zaidi, S., Kanchi, R. S., Rao, S., Gough, N. R., Schultz, A., Li, X., Lorenzi, P. L., Berger, A. C., Robertson, G., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.08.010 · Cited by 183 · cited 2×
“For example, TβRII mutations are frequently found in colorectal cancer (CRC),90 SMAD2 mutations have been reported in CRC, hepatocellular carcinoma (HCC), and lung cancer,91,92 and the deletion or mutation of SMAD4 is often identified in pancreatic cancer, CRC, and HCC.93,94 There are several advanced tumors that stil…”
BackgroundVardouli, L., Moustakas, A., & Stournaras, C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m402651200 · Cited by 182
Zilberberg, L., Todorovic, V., Dabovic, B., Horiguchi, M., Couroussé, T., Sakai, L. Y., & Rifkin, D. B. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24094 · Cited by 181
Dodagatta-Marri, E., Meyer, D. S., Reeves, M. Q., Paniagua, R., To, M. D., Binnewies, M., Broz, M. L., Mori, H., Wu, D., Adoumie, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0493-9 · Cited by 177 · cited 3×
“NIS793 is a pan anti-TGFβ-neutralizing antibody that is currently being tested in a phase 2 clinical trial for patients with metastatic PDAC in combination with gemcitabine/nabpaclitaxel chemotherapy (NCT04390763).(262) TβRI kinase inhibitors have also been combined with targeted therapies to overcome drug resistance…”
BackgroundInfluentialAsano, Y., Ihn, H., Yamane, K., Jinnin, M., & Tamaki, K. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.041306 · Cited by 175
Liu, S., González‐Prieto, R., Zhang, M., Geurink, P. P., Kooij, R., Iyengar, P. V., van Dinther, M., Bos, E., Zhang, X., Dévédec, S. E. L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1373 · Cited by 175
Kim, H. S., Mendiratta, S., Kim, J., Pecot, C. V., Larsen, J. E., Zubovych, I., Seo, B. Y., Kim, J., Eskiocak, B., Chung, H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.041 · Cited by 172
A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment
Huynh, L., Hipolito, C., & ten Dijke, P. (2019) · Biomolecules · doi:10.3390/biom9110743 · Cited by 171 · cited 1×
“Many preclinical results from in vitro cell models and in vivo animal models have shown the great potential of anti-tumor therapeutics with TGFβ-neutralizing antibodies and ligand traps that block the interaction of TGFβ with its receptors or selective small-molecule TGFβ receptor kinase inhibitors.(21,22) However, re…”
BackgroundSchwarz, J. K., Bassing, C. H., Kovesdi, I., Datto, M. B., Blazing, M., George, S., Wang, X. F., & Nevins, J. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.2.483 · Cited by 164
BMP signaling in vascular biology and dysfunction
García de Vinuesa, A., Abdelilah-Seyfried, S., Knaus, P., Zwijsen, A., & Bailly, S. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.12.005 · Cited by 164
Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2015.05.001 · Cited by 159
TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype
Fessler, E., Drost, J., van Hooff, S. R., Linnekamp, J. F., Wang, X., Jansen, M., De Sousa E Melo, F., Prasetyanti, P. R., IJspeert, J. E., Franitza, M., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606184 · Cited by 159 · cited 1×
“For example, by performing intermittent dosing strategies bypassing cardiovascular toxicity,(321,322) by specifically inhibiting only the TGFβ1 isoform that has the strongest link with cancer progression,(282) or by selecting cancer patients for treatment with a mesenchymal phenotype and high TGFβ activity that are li…”
BackgroundWeis-Garcia, F., & Massagué, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00358.x · Cited by 158
TGF-β Signaling in Myeloid Cells Is Required for Tumor Metastasis
Pang, Y., Gara, S. K., Achyut, B. R., Li, Z., Yan, H. H., Day, C.-P., Weiss, J. M., Trinchieri, G., Morris, J. C., & Yang, L. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0527 · Cited by 157 · cited 1×
“Indeed, experimentally induced inactivation of TGFβ signaling in myeloid cells can lead to an increase in antitumor activity.(175,176) TGFβ blocks the activation of NK cells and suppresses their cytotoxic potential by inhibiting C-type lectin receptor NKG2D expression directly and indirectly.”
Background
Research works printed but not linked: 3
- Derynck, R., Muthusamy, B. P. & Saeteurn, K. Y. Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition. Curr. Opin. Cell Biol. 31, 56–66 (2014). · DOI · Paper page
- Kim, H. S. et al. A phase I study of TGF-β inhibitor, vactosertib in combination with imatinib in patients with advanced desmoid tumor (aggressive fibromatosis). J. Clin. Oncol. 38, e11557 (2020). · DOI
- Derynck, R. & Budi, E. H. J. Ss Specificity, versatility, and control of TGF-β family signaling. Sci. Signal 12, eaav5183 (2019). · DOI · Paper page
Cited by
Targeting TGF-β signal transduction for fibrosis and cancer therapy
Peng, D., Fu, M., Wang, M., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01569-x · Cited by 1,065
“In recent years, scientists found that overexpressed TGF-β causes a plethora of metabolic disorders and dysfunction, and promotes epithelial-mesenchymal transition (EMT) and excessive deposition of ECM [5, 6], which causes immune dysfunction, fibrosis, and cancers [7].”
BackgroundHarnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Dynamic EMT: a multi‐tool for tumor progression
Brabletz, S., Schuhwerk, H., Brabletz, T., & Stemmler, M. P. (2021) · The EMBO Journal · doi:10.15252/embj.2021108647 · Cited by 761
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 670
Zhang, M., Ma, Y., Ye, X., Zhang, N., Pan, L., & Wang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01464-x · Cited by 522
Metadata
- Authors
- Liu, S., Ren, J., & ten Dijke, P.
- Affiliations
- Leiden University Medical Center (NL)
- ORCID
- Liu, Sijia
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2021-01-08
- Volume
- 6
- Issue
- 1
- Pages
- 8-8
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC7791126
- OpenAlex
- W3119664087
- Cited by
- 413
- References
- 330
- Citations by year
- 2026: 56 · 2025: 95 · 2024: 89 · 2023: 74 · 2022: 58 · 2021: 41
- FWCI
- 7.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Cancer Genomics Centre
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Kruppel-like factors research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- TGF-beta signaling, cancer therapy, tumor suppressor, tumor promoters, epithelial-mesenchymal transition, metastasis, tumor microenvironment, extracellular matrix deposition, angiogenesis, combination therapy, chemotherapy, targeted therapy, radiotherapy, immunotherapy
- MeSH terms
- Humans, Neoplasm Proteins, Neoplasms, Signal Transduction, Transforming Growth Factor beta, Epithelial-Mesenchymal Transition, Tumor Microenvironment, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.